Date: 2011-06-24
Type of information: R&D agreement
Compound: protein-activity based biomarkers using PhosphoScout® platform
Company: Evotec (Germany) Roche (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: research - R&D - collaboration
Action mechanism: This platform can monitor up to 15 000 changes in phosphorylation in a single study. It is used to explore signal transduction in living cells, whether in animal models or in patient tissue samples. Use of this approach to determine the signalling pathways affected by a candidate drug allows the mode of action to be investigated, for small molecules and biological compounds alike, and permits associated biomarkers to be identified. The technology is best suited to oncology as a majority of targeted therapies interfere with signal transduction pathways responsible for reversible phosphorylation.
Disease:
Details:
- Evotec and Roche have announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development. Evotec will employ its PhosphoScout® platform to discover protein-phosphorylation’s that predict favorable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials as well as assessing the development of companion diagnostics for patient stratification. Under the initial three-year term Evotec and Roche will conduct multiple biomarker programs for therapeutic antibodies or small molecule inhibitors.
Financial terms:
- Evotec will receive undisclosed up-front and success-based payments for each program.
Latest news:
- • On April 24, 2014, Evotec has announced the successful achievement of a milestone in its biomarker alliance with Roche. The milestone was achieved on the decision by Roche to use a response prediction marker, identified using Evotec’s Proteome Profiling platform, in an extended phase I oncology trial. This is the first minor milestone achieved under the collaboration and licence agreement between Evotec and Roche, signed in 2011, which is part of the m4 Munich Biotech Cluster Personalized Medicine and Targeted Therapies initiative funded by the German Federal Ministry of Education and Research. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programmes for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
Is general: Yes
